NetworkNewsBreaks – SenesTech Inc. (NASDAQ: SNES
Post# of 93
(Total Views: 155)
Posted On: 05/10/2024 5:04:08 PM
NetworkNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Releases Q1 2024 Report on Financial, Corporate Results
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R) products, is reporting its financial and operational results for first quarter 2024. Highlights of the report include record quarterly revenues of $415,000, up 78% from Q1 2023; Evolve(TM) becoming the company’s best-selling product, making up more than 50% of this quarter’s revenue; securing distribution and agreements as well as initial purchase orders with several grain-management and open-field agricultural distributors and pest-management industry distributors; global expansion with new sales in Hong Kong, Macau, the United Arab Emirates, Singapore, Australia, New Zealand and The Netherlands; the introduction of Evolve in convenient 1.5- and 3-lb. pouches; and the launch of Evolve(TM) Mouse to control mouse infestations. “I am extremely pleased with the rapid revenue growth during the first quarter of 78%, resulting in record quarterly revenues, driven by the rapid adoption in the marketplace of Evolve, our all-new soft bait product to control rat populations by restricting fertility,” said SenesTech president and CEO Joel Fruendt in the press release. “During the first quarter, Evolve accounted for more than 50% of sales, as distributors and end customers have quickly understood the benefits our new solution provides. . . . The last few months have been the most exciting and productive time in SenesTech’s history. . . . We are extremely pleased with the progress the team has made in 2024 and look forward to the positive impact the many recent initiatives we have implemented will produce.”
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://nnw.fm/SNES
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R) products, is reporting its financial and operational results for first quarter 2024. Highlights of the report include record quarterly revenues of $415,000, up 78% from Q1 2023; Evolve(TM) becoming the company’s best-selling product, making up more than 50% of this quarter’s revenue; securing distribution and agreements as well as initial purchase orders with several grain-management and open-field agricultural distributors and pest-management industry distributors; global expansion with new sales in Hong Kong, Macau, the United Arab Emirates, Singapore, Australia, New Zealand and The Netherlands; the introduction of Evolve in convenient 1.5- and 3-lb. pouches; and the launch of Evolve(TM) Mouse to control mouse infestations. “I am extremely pleased with the rapid revenue growth during the first quarter of 78%, resulting in record quarterly revenues, driven by the rapid adoption in the marketplace of Evolve, our all-new soft bait product to control rat populations by restricting fertility,” said SenesTech president and CEO Joel Fruendt in the press release. “During the first quarter, Evolve accounted for more than 50% of sales, as distributors and end customers have quickly understood the benefits our new solution provides. . . . The last few months have been the most exciting and productive time in SenesTech’s history. . . . We are extremely pleased with the progress the team has made in 2024 and look forward to the positive impact the many recent initiatives we have implemented will produce.”
NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://nnw.fm/SNES
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)